About Us

Luye Pharma Group (02186.HK), a member of Luye Life Sciences Group, is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications.

On The Road

Clinical Trials for Luye Pharma’s Licensed Drug Lurbinectedin to Begin in China Soon

News

Luye Pharma Group has announced that the clinical trials application for Lurbinectedin, an innovative anticancer drug licensed-in from PharmaMar, has been accepted by the Center for Drug Evaluation of China, for the treatment of Small Cell Lung Cancer.

June 29,2020

Luye Pharma to Start Clinical Trials for Its Next-Generation NTRK Inhibitor in China, The drug is expected to improve the treatment of patients with drug ...

Luye Pharma Group announced that its synthetic class one new drug LPM4870108 tablets (LY01018), a small-molecule inhibitor of NTRK with independent intellectual property right, has received formal acceptance of clinical trial application from the Center for Drug Evaluation of the National Medical Products Administration in China, and will begin clinical trials soon.

June 23,2020

Read More

Investors

Employee Stories

Upholding the philosophy of “Employee Development”,
Luye Pharma regards employees as the most valuable resources of the company